ECSP034436A - Sales de valsartan - Google Patents

Sales de valsartan

Info

Publication number
ECSP034436A
ECSP034436A EC2003004436A ECSP034436A ECSP034436A EC SP034436 A ECSP034436 A EC SP034436A EC 2003004436 A EC2003004436 A EC 2003004436A EC SP034436 A ECSP034436 A EC SP034436A EC SP034436 A ECSP034436 A EC SP034436A
Authority
EC
Ecuador
Prior art keywords
valsartan
salts
crystalline
salt
pharmaceutical preparations
Prior art date
Application number
EC2003004436A
Other languages
English (en)
Inventor
Erwin Marti
Peter Buehlmayer
Hans Rudolf Oswald
Wolfgang Marterer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP034436A publication Critical patent/ECSP034436A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a nuevas sales de valsartan, o sales cristalinas y también parcialmente cristalinas y amorfas de valsartan, a la producción y usos respectivos, y a preparaciones farmacéuticas que contienen dicha sal.
EC2003004436A 2000-07-19 2003-01-17 Sales de valsartan ECSP034436A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19

Publications (1)

Publication Number Publication Date
ECSP034436A true ECSP034436A (es) 2003-03-10

Family

ID=8169294

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004436A ECSP034436A (es) 2000-07-19 2003-01-17 Sales de valsartan

Country Status (30)

Country Link
US (5) US20030207930A1 (es)
EP (1) EP1313714B1 (es)
JP (1) JP4102664B2 (es)
KR (1) KR100529658B1 (es)
CN (2) CN1216873C (es)
AR (2) AR032758A1 (es)
AT (1) ATE406355T1 (es)
AU (2) AU2001289672B2 (es)
BR (1) BR0112665A (es)
CA (1) CA2415962C (es)
CY (1) CY1108559T1 (es)
CZ (1) CZ303389B6 (es)
DE (1) DE60135560D1 (es)
DK (1) DK1313714T3 (es)
EC (1) ECSP034436A (es)
ES (1) ES2309090T3 (es)
HU (1) HU229280B1 (es)
IL (2) IL153882A0 (es)
MX (1) MXPA03000525A (es)
MY (2) MY152846A (es)
NO (1) NO326504B1 (es)
NZ (1) NZ523557A (es)
PE (1) PE20020613A1 (es)
PL (1) PL205715B1 (es)
PT (1) PT1313714E (es)
RU (1) RU2275363C2 (es)
SI (1) SI1313714T1 (es)
SK (1) SK287558B6 (es)
WO (1) WO2002006253A1 (es)
ZA (1) ZA200300285B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1313714T3 (da) 2000-07-19 2008-12-15 Novartis Ag Valsartansalte
CA2472399C (en) * 2002-01-17 2012-02-21 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR20050000556A (ko) * 2002-05-17 2005-01-05 노파르티스 아게 심근 경색증의 속발 예방을 위한 안지오텐신 ｉｉ 수용체차단제 및 베타-차단제의 조합물
CA2486557A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
WO2004083192A1 (en) * 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Polymorphis of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
US20050165075A1 (en) * 2003-03-31 2005-07-28 Hetero Drugs Limited Novel amorphous form of valsartan
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
AU2005318365B2 (en) * 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
WO2007017897A2 (en) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
FR2886642B1 (fr) 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
DE602007000211D1 (de) * 2007-06-07 2008-12-11 Inke Sa Verfahren zur Gewinnung eines zur Gewinnung von Valsartan nützlichen Valsartan-Salzes
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
PL2295035T3 (pl) 2007-11-06 2016-11-30 Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)
WO2009064681A2 (en) 2007-11-12 2009-05-22 Novartis Ag Liquid compositions comprising valsartan
BR112013002589A2 (pt) 2010-08-03 2019-09-24 Novartis Ag valsatana altamente cristalina
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
JP5981940B2 (ja) * 2011-01-20 2016-08-31 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アジルサルタン有機アミン塩、その製造方法及び使用
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
KR20150119468A (ko) 2013-02-28 2015-10-23 더미라, 인코포레이티드 글리코피롤레이트 염
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
JP7022747B2 (ja) 2016-10-28 2022-02-18 バイオコン・リミテッド アモルファスサクビトリルバルサルタン三ナトリウムおよびその調製のためのプロセス
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019008485A1 (en) * 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
MX391562B (es) 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
WO2021111464A1 (en) * 2019-12-02 2021-06-10 Harman Finochem Limited A process for the preparation of highly pure valsartan

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
BR9507086A (pt) 1994-03-17 1997-09-16 Ciba Geigy Ag Tratamento de nefroterapia diabética com valsartan
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
AU5399096A (en) 1995-04-07 1996-10-23 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
DE69624253T2 (de) * 1995-10-06 2003-08-07 Novartis Ag, Basel Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DK1313714T3 (da) 2000-07-19 2008-12-15 Novartis Ag Valsartansalte

Also Published As

Publication number Publication date
US20070149587A1 (en) 2007-06-28
EP1313714A1 (en) 2003-05-28
CA2415962C (en) 2010-07-06
NZ523557A (en) 2004-12-24
IL153882A (en) 2009-09-01
ES2309090T3 (es) 2008-12-16
HUP0300731A3 (en) 2006-05-29
CA2415962A1 (en) 2002-01-24
US9499499B2 (en) 2016-11-22
HUP0300731A2 (hu) 2003-09-29
NO20030232D0 (no) 2003-01-17
ATE406355T1 (de) 2008-09-15
PL360737A1 (en) 2004-09-20
RU2275363C2 (ru) 2006-04-27
ZA200300285B (en) 2004-03-25
MY152846A (en) 2014-11-28
BR0112665A (pt) 2003-06-24
CN1443176A (zh) 2003-09-17
MXPA03000525A (es) 2003-05-14
CN100413852C (zh) 2008-08-27
DK1313714T3 (da) 2008-12-15
US20120329844A1 (en) 2012-12-27
US20140073677A1 (en) 2014-03-13
PE20020613A1 (es) 2002-08-07
KR100529658B1 (ko) 2005-11-21
SK287558B6 (sk) 2011-02-04
SK552003A3 (en) 2003-07-01
DE60135560D1 (de) 2008-10-09
US8278339B2 (en) 2012-10-02
CZ2003117A3 (cs) 2003-05-14
CY1108559T1 (el) 2014-04-09
HK1055963A1 (en) 2004-01-30
CN1680341A (zh) 2005-10-12
IL153882A0 (en) 2003-07-31
CZ303389B6 (cs) 2012-08-29
HU229280B1 (en) 2013-10-28
NO326504B1 (no) 2008-12-15
EP1313714B1 (en) 2008-08-27
JP2004504307A (ja) 2004-02-12
AR032758A1 (es) 2003-11-26
MY136446A (en) 2008-10-31
US20080293791A1 (en) 2008-11-27
PL205715B1 (pl) 2010-05-31
SI1313714T1 (sl) 2009-02-28
AU8967201A (en) 2002-01-30
PT1313714E (pt) 2008-11-03
WO2002006253A1 (en) 2002-01-24
KR20030015888A (ko) 2003-02-25
AU2001289672B2 (en) 2005-12-08
AR069374A2 (es) 2010-01-20
NO20030232L (no) 2003-01-17
US20030207930A1 (en) 2003-11-06
CN1216873C (zh) 2005-08-31
JP4102664B2 (ja) 2008-06-18

Similar Documents

Publication Publication Date Title
ECSP034436A (es) Sales de valsartan
ECSP045221A (es) Sales de valsartan
BR0111319A (pt) Composto, processo para preparar um composto, uso de um composto, processo para preparar um sal de um composto, e, composto intermediário
HN2001000281A (es) Nuevas imidazotriazinonas sustituidas
DE60100143D1 (de) Freisetzungssystem von Cyclopropenderivaten, welches eine kleinere Wassermenge benützt
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
SV2002000356A (es) Nuevos derivados de piperazina ref. pc10770aixn/bb
PA8436201A1 (es) Derivados 6,5-heterobiciclicos sustituidos
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
HN2000000115A (es) Formulacion de sal comun y moxifloxacina
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
AR003476A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol
CR7576A (es) Nuevas sales de perindopril y composiciones farmaceuticas que las contienen
ES2116651T3 (es) Sal de l-carnitina y composiciones que la contienen.
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
DK0744397T3 (da) Fluorphenylsubstituerede alkenylcarboxylsyre-guanidiner som Na+/K+-antiport-inhibitorer, deres anvendelse som lægemiddel el
BR0210912A (pt) Compostos e composições como inibidores de catepsina
BR9916887A (pt) Uso de derivados de pirimidina
BR0312996A (pt) Sal de (s)-pantoprazol e seus hidratos
ES2075454T3 (es) Forma cristalina pura de rifapentina.
BR0107483A (pt) Processo para a preparação de um composto
AR037967A1 (es) Utilizacion de desoxipeganina en el tratamiento de la depresion clinica
PA8511401A1 (es) Nuevos derivados de amidas heterociclicas
BR9911969A (pt) Sal e processos para a preparação de um sal, para a preparação de acetato de n-terc-butilhidroxilamina, para o isolamento de acetato de n-terc- butilhidroxilamina, e para a purificação do acetato de n-terc- butilhidroxilamina